In response to Canadian research showing that the high price of cervical cancer vaccines was a key reason why the majority of young Canadian women have yet to be immunized, the manufacturer of Cervarix cut the cost of the vaccine by 30% effective October 25, 2010. GlaxoSmithKline, Inc, reduced the price from $134.95/dose to $90.00/dose; 3 doses are recommended.
